{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:01:50Z","timestamp":1782244910471,"version":"3.54.5"},"reference-count":21,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,10,26]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>A 63-year-old woman with grade 2 infiltrating left breast carcinoma who was started on ribociclib complained of exertional dyspnoea along with dry cough. There were bilateral interscapular crackles and chest X-ray evidence of bilateral mid and lower zone non-homogeneous opacity. The patient\u2019s pulmonary function test (PFT) showed moderate restrictions and desaturation. CT was suggestive of organising pneumonia and drug administration was stopped. The patient was treated with steroids in tapering doses, which led to improvements. The drug was restarted with the probability of other aetiologies for interstetial lung disease (ILD). It was also considered the superior efficacy of ribociclib in managing breast cancer. But due to evidence indicating the reappearance of organising pneumonia following drug administration, it was again stopped, and steroid use was restarted for treatment. The patient showed improvements in subsequent follow-ups.<\/jats:p>","DOI":"10.1136\/bcr-2021-245187","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T13:25:57Z","timestamp":1640006757000},"page":"e245187","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Ribociclib-associated organising pneumonia"],"prefix":"10.1136","volume":"14","author":[{"given":"Arjun","family":"Rajendran","sequence":"first","affiliation":[{"name":"Pharmacy Practice, Amrita School of Pharmacy, Amrita Institute of Medical Sciences and Research Centre, Cochin, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Kunoor","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Amrita Institute of Medical Science, Amrita Viswa Vidyapeetham, Cochin, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshini","family":"Pushpa Ragahavan","sequence":"additional","affiliation":[{"name":"Pharmacy Practice, Amrita School of Pharmacy, Amrita Institute of Medical Sciences and Research Centre, Cochin, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavithran","family":"Keechilat","sequence":"additional","affiliation":[{"name":"Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Cochin, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"2025082709021831000_14.12.e245187.1","doi-asserted-by":"publisher","DOI":"10.1148\/radiographics.20.5.g00se081245"},{"key":"2025082709021831000_14.12.e245187.2","first-page":"2","article-title":"Radiological imaging of drug-induced PulmonaryLesions","volume":"2","author":"D\u2019souza","year":"2018","journal-title":"J Clin Radiol Case Rep"},{"key":"2025082709021831000_14.12.e245187.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diii.2014.01.004"},{"key":"2025082709021831000_14.12.e245187.4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155"},{"key":"2025082709021831000_14.12.e245187.5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.breast.2020.10.007","article-title":"Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia","volume":"54","author":"Fuentes-Antr\u00e1s","year":"2020","journal-title":"Breast"},{"key":"2025082709021831000_14.12.e245187.6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-018-1050-7","article-title":"Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial","volume":"20","author":"Hortobagyi","year":"2018","journal-title":"Breast Cancer Res"},{"key":"2025082709021831000_14.12.e245187.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-5231(03)00140-0"},{"key":"2025082709021831000_14.12.e245187.8","unstructured":"U.S. Food and Drug Administration . Fda warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer: FDA drug safety communication, 2019."},{"key":"2025082709021831000_14.12.e245187.9","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000246"},{"key":"2025082709021831000_14.12.e245187.10","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918786451","article-title":"Cdk4\/6 inhibition in breast cancer: current practice and future directions","volume":"10","author":"Pernas","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2025082709021831000_14.12.e245187.11","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1111\/cas.14554","article-title":"Ribociclib, a CDK 4\/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer","volume":"111","author":"Yap","year":"2020","journal-title":"Cancer Sci"},{"key":"2025082709021831000_14.12.e245187.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-020-01433-w","article-title":"Cdk4\/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis","volume":"21","author":"Birnhuber","year":"2020","journal-title":"Respir Res"},{"key":"2025082709021831000_14.12.e245187.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000507647","article-title":"Ribociclib-Induced pneumonitis: a case report","volume":"16","author":"Algwaiz","year":"2021","journal-title":"Breast Care"},{"key":"2025082709021831000_14.12.e245187.14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14737140.2019.1674651","article-title":"Can CDK4\/6 inhibitors cause fatal lung injury?","volume":"19","author":"Jazieh","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025082709021831000_14.12.e245187.15","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00027607"},{"key":"2025082709021831000_14.12.e245187.16","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/jbmr.4030","article-title":"Nitrogen-Containing bisphosphonates are associated with reduced risk of pneumonia in patients with hip fracture","volume":"35","author":"Sing","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2025082709021831000_14.12.e245187.17","doi-asserted-by":"crossref","unstructured":"MD LO , MD PE , MD SY . Fatal Palbociclib -related interstitial pneumonitis. Archives of Clinical and Medical Case Reports 2019;03.doi:10.26502\/acmcr.96550075","DOI":"10.26502\/acmcr.96550075"},{"key":"2025082709021831000_14.12.e245187.18","article-title":"Palbociclib related pneumotoxicity: a rare side effect","volume":"195","author":"Ahsan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2025082709021831000_14.12.e245187.19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10549-017-4606-9","article-title":"A single institution experience with palbociclib toxicity requiring dose modifications","volume":"168","author":"Gong","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2025082709021831000_14.12.e245187.20","unstructured":"Wilgus M-L , Rosenberg J . Cdk4\/6 inhibitor-induced pneumonitis: a case report and review of the literature. Proceedings of UCLA Health-VOLUME, 2020."},{"key":"2025082709021831000_14.12.e245187.21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10549-020-06001-w","article-title":"Cyclin-Dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment","volume":"186","author":"Raschi","year":"2021","journal-title":"Breast Cancer Res Treat"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-245187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:02:26Z","timestamp":1756310546000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-245187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":21,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,20]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/bcr-2021-245187"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-245187","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}